Literature DB >> 25325929

Intrathyroidal tumors presenting with extranodal extension: what are we missing?

Jason B Clain1, Saral Mehra, Sophie Scherl, Laura L Dos Reis, A Turk, Bruce M Wenig, Eliza H Dewey, Mark L Urken.   

Abstract

Extranodal extension (ENE) is an indicator of poor prognosis in well-differentiated thyroid cancer (WDTC). We have demonstrated that extrathyroidal extension (ETE) predicts ENE in patients with positive lymph nodes, indicating concordance between primary tumor and lymph node biology. In an effort to determine if there were other histologic features of the primary tumors that indicated an aggressive biology, we examined a subset of patients with intrathyroidal (T1/T2) disease whose lymph nodes had ENE. A review was conducted from January 2004 to March 2013. The histologic features of ETE-negative/ENE-positive tumors (group A, 12 cases) were compared with a random sample of ETE-negative/ENE-negative node-positive patients (group B, 27 cases). Cases were reviewed for size, capsule presence, infiltration, sclerosis, lymphocytic thyroiditis (LT), psammoma bodies, lymphovascular invasion (LVI), perineural invasion (PNI), architecture/cytomorphology, and focality. Size was compared using the Mann-Whitney test, while the remaining features were compared using a Fischer exact test. The breakdown of pathologic features of groups A/B were as follows: 2.28 cm/1.46 cm mean tumor size, 90 %/67 % unencapsulated, 100 %/89 % infiltrative, 100 %/89 % sclerotic, 60 %/52 % LT, 30 %/59 % positive psammoma bodies, 0 %/11 % LVI, 0 %/4 % PNI, 90 %/96 % classic architecture, 50 %/44 % multifocal. Neither size (p = 0.072) nor the other nine histologic features examined reached statistical significance. None of the histologic features appeared to significantly predict ENE. Further examination of intrathyroidal tumors at a molecular level is necessary to determine if there are any identifiable features of intrathyroidal tumors that predict ENE and thus a more aggressive phenotype.

Entities:  

Mesh:

Year:  2014        PMID: 25325929     DOI: 10.1007/s12022-014-9340-9

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  30 in total

1.  Prognosis of low-risk papillary thyroid carcinoma patients: its relationship with the size of primary tumors.

Authors:  Yasuhiro Ito; Takumi Kudo; Minoru Kihara; Yuuki Takamura; Kaoru Kobayashi; Akihiro Miya; Akira Miyauchi
Journal:  Endocr J       Date:  2011-11-09       Impact factor: 2.349

2.  Risk factors for recurrence to the lymph node in papillary thyroid carcinoma patients without preoperatively detectable lateral node metastasis: validity of prophylactic modified radical neck dissection.

Authors:  Yasuhiro Ito; Takuya Higashiyama; Yuuki Takamura; Akihiro Miya; Kaoru Kobayashi; Fumio Matsuzuka; Kanji Kuma; Akira Miyauchi
Journal:  World J Surg       Date:  2007-11       Impact factor: 3.352

3.  Increasing incidence of thyroid cancer in the United States, 1973-2002.

Authors:  Louise Davies; H Gilbert Welch
Journal:  JAMA       Date:  2006-05-10       Impact factor: 56.272

4.  Predictive factors for lymph node metastasis in solitary papillary thyroid carcinomas: a retrospective study.

Authors:  Fábio Muradás Girardi; Marinez Bizarro Barra; Cláudio Galleano Zettler
Journal:  Pathol Oncol Res       Date:  2014-05-02       Impact factor: 3.201

5.  The utility of routine frozen section examination for intraoperative diagnosis of thyroid cancer.

Authors:  C R McHenry; C Raeburn; T Strickland; J J Marty
Journal:  Am J Surg       Date:  1996-12       Impact factor: 2.565

6.  Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis.

Authors:  Sophie Leboulleux; Carole Rubino; Eric Baudin; Bernard Caillou; Dana M Hartl; Jean-Michel Bidart; Jean-Paul Travagli; Martin Schlumberger
Journal:  J Clin Endocrinol Metab       Date:  2005-07-19       Impact factor: 5.958

7.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; S M Jhiang
Journal:  Am J Med       Date:  1994-11       Impact factor: 4.965

8.  Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma.

Authors:  Xiaolong Lee; Ming Gao; Yifeng Ji; Yang Yu; Ying Feng; Yigong Li; Yan Zhang; Wenyuan Cheng; Wenchuan Zhao
Journal:  Ann Surg Oncol       Date:  2008-11-26       Impact factor: 5.344

9.  Extranodal tumor extension to adjacent organs predicts a worse cause-specific survival in patients with papillary thyroid carcinoma.

Authors:  Yasuhiro Ito; Mitsuyoshi Hirokawa; Tomoo Jikuzono; Takuya Higashiyama; Yuuki Takamura; Akihiro Miya; Kaoru Kobayashi; Fumio Matsuzuka; Kanji Kuma; Akira Miyauchi
Journal:  World J Surg       Date:  2007-06       Impact factor: 3.282

10.  Central lymph node metastasis is an important prognostic factor in patients with papillary thyroid microcarcinoma.

Authors:  Jeonghun Lee; Yeongpeck Song; Euy Young Soh
Journal:  J Korean Med Sci       Date:  2013-12-26       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.